Vanda Pharmaceuticals Welcomes Dr. Charles Duncan to Board of Directors

Vanda Pharmaceuticals Inc., a notable player in the global biopharmaceutical sector, has officially announced the appointment of Dr. Charles Duncan to its Board of Directors, effective April 22, 2026. This strategic move adds a seasoned expert to its leadership team as the company continues to enhance its focus on addressing significant unmet medical needs through innovative therapies.

With Dr. Duncan now on board, Vanda's Board comprises seven directors, six of whom are independent, solidifying its governance structure. The company’s President, CEO, and Chairman of the Board, Mihael H. Polymeropoulos, expressed enthusiasm about Dr. Duncan’s appointment, highlighting his vast experience and respected standing in the life sciences and biotechnology sectors. His foundational understanding of the industry is expected to complement Vanda's efforts in advancing its innovative pipeline.

Dr. Duncan brings with him a distinguished career that includes his current role as President of Sulci Advisors, LLC, a business advisory firm he founded in September 2025, focusing on life sciences. Before establishing Sulci Advisors, he dedicated nearly 30 years to the role of a sell-side biotechnology equity research analyst. As the Managing Director and Senior Biotechnology Analyst at Cantor Fitzgerald & Co., he managed coverage for over 70 companies, concentrating on neurology and psychiatry while enhancing therapeutic platforms.

His prior affiliations also include prominent positions at Piper Jaffray & Co., where he was recognized as a distinguished analyst by Thomson Reuters StarMine, and at JMP Securities, LLC, where he co-founded the healthcare partnership and initiated its biotechnology research franchise. Dr. Duncan's extensive background offers Vanda a significant edge as it navigates its promising developments in therapy.

Dr. Duncan's academic credentials include a Ph.D. in Pharmaceutical Sciences, concentrating on Neuropharmacology, obtained from the University of Colorado-Boulder, as well as a Bachelor of Science in Zoology from the University of Wisconsin-Madison. His diverse industry experience positions him uniquely to contribute to Vanda's direction and decision-making processes.

Upon joining, Dr. Duncan expressed his excitement about contributing to Vanda during what he considers a potentially transformative phase for the company. He noted the impressive legacy of innovation that Vanda has established in central nervous system (CNS) disorders. With the recent approvals of NEREUS™ and BYSANTI™, alongside the expansion of the Fanapt® label, Dr. Duncan sees an era of growth on the horizon for Vanda. He anticipates active and productive board service focused on enhancing value for all stakeholders, including patients, payors, and shareholders.

As Vanda continues to pursue advancements in its therapeutic pipeline, Dr. Duncan's appointment is seen as a significant step toward achieving the company's vision of improving patient outcomes through innovative solutions.

For more information about Vanda Pharmaceuticals Inc. and its commitment to addressing unmet medical needs, please visit Vanda Pharmaceuticals and follow them on X @vandapharma.